NCT06951646: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Sponsor: Second Xiangya Hospital of Central South University. Phase: PHASE2. Conditions: Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)